Clinical trial
Safety, Tolerability and Immunogenicity of Pneumovax 23 in Healthy Adults in…
NCT00496093 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00496093 |
|---|---|
| Title | Safety, Tolerability and Immunogenicity of Pneumovax 23 in Healthy Adults in India (V110-011) |
| Official title | Safety, Tolerability and Immunogenicity of Pneumovax 23 (V110) in Healthy Adults in India |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pneumococcal Infection |
| Intervention type | Biological |
| Interventions | Pneumococcal Vaccine, Polyvalent (23-valent) |
| Enrollment | 133 |
| Start date | Oct 1, 2005 |
| Primary completion | Jan 1, 2006 |
| Completion | Jan 1, 2006 |
| First posted | Jul 4, 2007 |
| Last update posted | Mar 14, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: